25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

PRPH (ProPhase Labs Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze ProPhase Labs Inc together

I guess you are interested in ProPhase Labs Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – ProPhase Labs Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – ProPhase Labs Inc’s Price Targets

I'm going to help you getting a better view of ProPhase Labs Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about ProPhase Labs Inc

I send you an email if I find something interesting about ProPhase Labs Inc.

1. Quick Overview

1.1. Quick analysis of ProPhase Labs Inc (30 sec.)










1.2. What can you expect buying and holding a share of ProPhase Labs Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
45.0%

What is your share worth?

Current worth
$0.28
Expected worth in 1 year
$-0.51
How sure are you?
47.5%

+ What do you gain per year?

Total Gains per Share
$-0.79
Return On Investment
-182.8%

For what price can you sell your share?

Current Price per Share
$0.43
Expected price per share
$0.2774 - $0.9349
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of ProPhase Labs Inc (5 min.)




Live pricePrice per Share (EOD)
$0.43
Intrinsic Value Per Share
$-7.76 - $-0.50
Total Value Per Share
$-7.49 - $-0.22

2.2. Growth of ProPhase Labs Inc (5 min.)




Is ProPhase Labs Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$11.4m$48.6m-$30.6m-170.4%

How much money is ProPhase Labs Inc making?

Current yearPrevious yearGrowGrow %
Making money-$10.3m-$6.5m-$3.7m-36.5%
Net Profit Margin273.1%-183.2%--

How much money comes from the company's main activities?

2.3. Financial Health of ProPhase Labs Inc (5 min.)




2.4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of ProPhase Labs Inc?

Welcome investor! ProPhase Labs Inc's management wants to use your money to grow the business. In return you get a share of ProPhase Labs Inc.

First you should know what it really means to hold a share of ProPhase Labs Inc. And how you can make/lose money.

Speculation

The Price per Share of ProPhase Labs Inc is $0.4299. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of ProPhase Labs Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in ProPhase Labs Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.28. Based on the TTM, the Book Value Change Per Share is $-0.20 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of ProPhase Labs Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.11-25.0%-0.25-58.0%-0.16-36.8%-0.14-33.7%-0.05-12.7%-0.01-1.9%
Usd Book Value Change Per Share-0.09-20.6%-0.20-45.7%-0.09-21.3%-0.11-26.5%0.000.2%0.000.4%
Usd Dividend Per Share0.000.0%0.000.0%0.0510.6%0.037.9%0.0615.0%0.0613.6%
Usd Total Gains Per Share-0.09-20.6%-0.20-45.7%-0.05-10.6%-0.08-18.6%0.0715.1%0.0614.1%
Usd Price Per Share0.39-0.99-4.89-4.94-5.88-4.02-
Price to Earnings Ratio-0.91--0.97--7.99-13.84-10.58-17.09-
Price-to-Total Gains Ratio-4.41--5.04--1.22--49.45--48.28-67.10-
Price to Book Ratio1.42-2.36-4.24-4.16-6.62-6.55-
Price-to-Total Gains Ratio-4.41--5.04--1.22--49.45--48.28-67.10-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.4299
Number of shares2326
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.06
Usd Book Value Change Per Share-0.200.00
Usd Total Gains Per Share-0.200.07
Gains per Quarter (2326 shares)-456.90151.38
Gains per Year (2326 shares)-1,827.60605.52
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1828-18385996596
20-3655-36661199121202
30-5483-54941798181808
40-7310-73222398242414
50-9138-91502997303020
60-10966-109783597363626
70-12793-128064196424232
80-14621-146344796494838
90-16448-164625395555444
100-18276-182905994616050

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%3.09.00.025.0%8.012.00.040.0%13.027.00.032.5%46.068.01.040.0%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%6.014.00.030.0%11.029.00.027.5%47.068.00.040.9%
Dividend per Share0.00.04.00.0%3.00.09.025.0%11.00.09.055.0%18.00.022.045.0%18.00.097.015.7%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%10.010.00.050.0%19.021.00.047.5%55.060.00.047.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of ProPhase Labs Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.089-0.196+122%-0.091+3%-0.114+28%0.001-13687%0.002-4891%
Book Value Per Share--0.2750.434-36%1.172-77%1.038-73%1.060-74%0.759-64%
Current Ratio--0.95910.635-91%2.194-56%5.529-83%5.063-81%7.724-88%
Debt To Asset Ratio--0.7280.724+1%0.470+55%0.506+44%0.467+56%0.327+123%
Debt To Equity Ratio--2.6763.499-24%0.905+196%1.630+64%1.293+107%0.797+236%
Dividend Per Share----0%0.046-100%0.034-100%0.064-100%0.059-100%
Enterprise Value---14178928.440-2333568.690-84%162534762.000-109%172911193.437-108%223621358.162-106%160294362.098-109%
Eps---0.108-0.249+132%-0.158+47%-0.145+34%-0.054-49%-0.008-92%
Ev To Ebitda Ratio--0.9100.172+429%-6.495+814%-0.250+127%-16.341+1895%-5.550+710%
Ev To Sales Ratio---2.8430.053-5473%10.841-126%5.167-155%5.736-150%7.697-137%
Free Cash Flow Per Share---0.020-0.071+249%-0.107+426%-0.072+254%-0.042+107%-0.026+26%
Free Cash Flow To Equity Per Share---0.014-0.024+70%-0.036+159%-0.055+291%0.050-128%0.002-741%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.908+10%1.026-3%
Intrinsic Value_10Y_max---0.499----------
Intrinsic Value_10Y_min---7.761----------
Intrinsic Value_1Y_max---0.095----------
Intrinsic Value_1Y_min---0.373----------
Intrinsic Value_3Y_max---0.251----------
Intrinsic Value_3Y_min---1.479----------
Intrinsic Value_5Y_max---0.365----------
Intrinsic Value_5Y_min---2.967----------
Market Cap17858561.880+9%16255071.56041257681.310-61%202928762.000-92%205292110.103-92%244236708.162-93%166960937.098-90%
Net Profit Margin---3.5862.731-231%-1.832-49%0.274-1407%0.162-2309%1.389-358%
Operating Margin---4.276-2.423-43%-2.353-45%-1.630-62%-0.970-77%-0.636-85%
Operating Ratio--3.7111.825+103%3.366+10%2.102+77%1.667+123%1.481+151%
Pb Ratio1.562+9%1.4212.362-40%4.237-66%4.163-66%6.616-79%6.547-78%
Pe Ratio-0.998-10%-0.909-0.974+7%-7.993+780%13.839-107%10.583-109%17.088-105%
Price Per Share0.430+9%0.3910.993-61%4.885-92%4.942-92%5.879-93%4.019-90%
Price To Free Cash Flow Ratio-5.290-10%-4.815-3.597-25%-14.851+208%-173.739+3508%-115.880+2307%-53.871+1019%
Price To Total Gains Ratio-4.850-10%-4.415-5.042+14%-1.222-72%-49.446+1020%-48.283+994%67.100-107%
Quick Ratio--0.79111.818-93%1.898-58%5.803-86%5.133-85%8.714-91%
Return On Assets---0.106-0.161+51%-0.072-33%-0.082-23%-0.038-64%-0.017-84%
Return On Equity---0.391-1.244+218%-0.137-65%-0.466+19%-0.267-32%-0.136-65%
Total Gains Per Share---0.089-0.196+122%-0.046-49%-0.080-10%0.065-236%0.060-247%
Usd Book Value--11436000.00018008250.000-36%48688500.000-77%43128083.333-73%44037350.000-74%31509125.000-64%
Usd Book Value Change Per Share---0.089-0.196+122%-0.091+3%-0.114+28%0.001-13687%0.002-4891%
Usd Book Value Per Share--0.2750.434-36%1.172-77%1.038-73%1.060-74%0.759-64%
Usd Dividend Per Share----0%0.046-100%0.034-100%0.064-100%0.059-100%
Usd Enterprise Value---14178928.440-2333568.690-84%162534762.000-109%172911193.437-108%223621358.162-106%160294362.098-109%
Usd Eps---0.108-0.249+132%-0.158+47%-0.145+34%-0.054-49%-0.008-92%
Usd Free Cash Flow---844000.000-2941750.000+249%-4436750.000+426%-2989916.667+254%-1747500.000+107%-1061350.000+26%
Usd Free Cash Flow Per Share---0.020-0.071+249%-0.107+426%-0.072+254%-0.042+107%-0.026+26%
Usd Free Cash Flow To Equity Per Share---0.014-0.024+70%-0.036+159%-0.055+291%0.050-128%0.002-741%
Usd Market Cap17858561.880+9%16255071.56041257681.310-61%202928762.000-92%205292110.103-92%244236708.162-93%166960937.098-90%
Usd Price Per Share0.430+9%0.3910.993-61%4.885-92%4.942-92%5.879-93%4.019-90%
Usd Profit---4472000.000-10363000.000+132%-6577500.000+47%-6010666.667+34%-2365050.000-47%-384200.000-91%
Usd Revenue--1247000.000835000.000+49%4493000.000-72%8321250.000-85%13226150.000-91%8411725.000-85%
Usd Total Gains Per Share---0.089-0.196+122%-0.046-49%-0.080-10%0.065-236%0.060-247%
 EOD+5 -3MRQTTM+21 -16YOY+13 -263Y+16 -235Y+9 -3110Y+7 -33

3.3 Fundamental Score

Let's check the fundamental score of ProPhase Labs Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.998
Price to Book Ratio (EOD)Between0-11.562
Net Profit Margin (MRQ)Greater than0-3.586
Operating Margin (MRQ)Greater than0-4.276
Quick Ratio (MRQ)Greater than10.791
Current Ratio (MRQ)Greater than10.959
Debt to Asset Ratio (MRQ)Less than10.728
Debt to Equity Ratio (MRQ)Less than12.676
Return on Equity (MRQ)Greater than0.15-0.391
Return on Assets (MRQ)Greater than0.05-0.106
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of ProPhase Labs Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.450
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About ProPhase Labs Inc

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Fundamental data was last updated by Penke on 2025-09-05 05:46:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ ProPhase Labs Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ ProPhase Labs Inc to theΒ Diagnostics & Research industry mean.
  • A Net Profit Margin of -358.6%Β means thatΒ $-3.59 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ProPhase Labs Inc:

  • The MRQ is -358.6%. The company is making a huge loss. -2
  • The TTM is 273.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ-358.6%TTM273.1%-631.7%
TTM273.1%YOY-183.2%+456.3%
TTM273.1%5Y16.2%+256.9%
5Y16.2%10Y138.9%-122.6%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-358.6%-2.6%-356.0%
TTM273.1%-6.5%+279.6%
YOY-183.2%-5.2%-178.0%
3Y27.4%-9.2%+36.6%
5Y16.2%-3.1%+19.3%
10Y138.9%-1.6%+140.5%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ ProPhase Labs Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ ProPhase Labs Inc to theΒ Diagnostics & Research industry mean.
  • -10.6% Return on Assets means thatΒ ProPhase Labs Inc generatedΒ $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ProPhase Labs Inc:

  • The MRQ is -10.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -16.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.6%TTM-16.1%+5.4%
TTM-16.1%YOY-7.2%-8.9%
TTM-16.1%5Y-3.8%-12.2%
5Y-3.8%10Y-1.7%-2.1%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.6%-0.6%-10.0%
TTM-16.1%-1.2%-14.9%
YOY-7.2%-1.1%-6.1%
3Y-8.2%-1.3%-6.9%
5Y-3.8%0.2%-4.0%
10Y-1.7%0.2%-1.9%
4.3.1.3. Return on Equity

Shows how efficient ProPhase Labs Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ ProPhase Labs Inc to theΒ Diagnostics & Research industry mean.
  • -39.1% Return on Equity means ProPhase Labs Inc generated $-0.39Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ProPhase Labs Inc:

  • The MRQ is -39.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -124.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-39.1%TTM-124.4%+85.3%
TTM-124.4%YOY-13.7%-110.7%
TTM-124.4%5Y-26.7%-97.7%
5Y-26.7%10Y-13.6%-13.1%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-39.1%-0.1%-39.0%
TTM-124.4%-0.9%-123.5%
YOY-13.7%-0.7%-13.0%
3Y-46.6%-1.9%-44.7%
5Y-26.7%-1.2%-25.5%
10Y-13.6%-1.1%-12.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of ProPhase Labs Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient ProPhase Labs Inc is operatingΒ .

  • Measures how much profit ProPhase Labs Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ ProPhase Labs Inc to theΒ Diagnostics & Research industry mean.
  • An Operating Margin of -427.6%Β means the company generated $-4.28 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ProPhase Labs Inc:

  • The MRQ is -427.6%. The company is operating very inefficient. -2
  • The TTM is -242.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-427.6%TTM-242.3%-185.3%
TTM-242.3%YOY-235.3%-7.0%
TTM-242.3%5Y-97.0%-145.3%
5Y-97.0%10Y-63.6%-33.4%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-427.6%-10.0%-417.6%
TTM-242.3%-12.4%-229.9%
YOY-235.3%-10.8%-224.5%
3Y-163.0%-0.3%-162.7%
5Y-97.0%3.0%-100.0%
10Y-63.6%2.9%-66.5%
4.3.2.2. Operating Ratio

Measures how efficient ProPhase Labs Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Diagnostics & Research industry mean).
  • An Operation Ratio of 3.71 means that the operating costs are $3.71 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of ProPhase Labs Inc:

  • The MRQ is 3.711. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.825. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.711TTM1.825+1.886
TTM1.825YOY3.366-1.541
TTM1.8255Y1.667+0.158
5Y1.66710Y1.481+0.187
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7111.299+2.412
TTM1.8251.311+0.514
YOY3.3661.238+2.128
3Y2.1021.260+0.842
5Y1.6671.212+0.455
10Y1.4811.148+0.333
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of ProPhase Labs Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if ProPhase Labs Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Diagnostics & Research industry mean).
  • A Current Ratio of 0.96Β means the company has $0.96 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of ProPhase Labs Inc:

  • The MRQ is 0.959. The company is just not able to pay all its short-term debts. -1
  • The TTM is 10.635. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ0.959TTM10.635-9.676
TTM10.635YOY2.194+8.440
TTM10.6355Y5.063+5.571
5Y5.06310Y7.724-2.661
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9591.969-1.010
TTM10.6352.158+8.477
YOY2.1942.291-0.097
3Y5.5292.421+3.108
5Y5.0632.689+2.374
10Y7.7243.137+4.587
4.4.3.2. Quick Ratio

Measures if ProPhase Labs Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ ProPhase Labs Inc to theΒ Diagnostics & Research industry mean.
  • A Quick Ratio of 0.79Β means the company can pay off $0.79 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ProPhase Labs Inc:

  • The MRQ is 0.791. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 11.818. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.791TTM11.818-11.027
TTM11.818YOY1.898+9.920
TTM11.8185Y5.133+6.685
5Y5.13310Y8.714-3.581
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7911.152-0.361
TTM11.8181.229+10.589
YOY1.8981.414+0.484
3Y5.8031.620+4.183
5Y5.1331.899+3.234
10Y8.7142.242+6.472
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of ProPhase Labs Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of ProPhase Labs IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ ProPhase Labs Inc to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 0.73Β means that ProPhase Labs Inc assets areΒ financed with 72.8% credit (debt) and the remaining percentage (100% - 72.8%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of ProPhase Labs Inc:

  • The MRQ is 0.728. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.724. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.728TTM0.724+0.004
TTM0.724YOY0.470+0.254
TTM0.7245Y0.467+0.256
5Y0.46710Y0.327+0.140
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7280.401+0.327
TTM0.7240.426+0.298
YOY0.4700.397+0.073
3Y0.5060.389+0.117
5Y0.4670.413+0.054
10Y0.3270.444-0.117
4.5.4.2. Debt to Equity Ratio

Measures ifΒ ProPhase Labs Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ ProPhase Labs Inc to theΒ Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 267.6% means that company has $2.68 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ProPhase Labs Inc:

  • The MRQ is 2.676. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.499. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.676TTM3.499-0.822
TTM3.499YOY0.905+2.594
TTM3.4995Y1.293+2.205
5Y1.29310Y0.797+0.496
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6760.622+2.054
TTM3.4990.598+2.901
YOY0.9050.627+0.278
3Y1.6300.654+0.976
5Y1.2930.636+0.657
10Y0.7970.660+0.137
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings ProPhase Labs Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ ProPhase Labs Inc to theΒ Diagnostics & Research industry mean.
  • A PE ratio of -0.91 means the investor is paying $-0.91Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ProPhase Labs Inc:

  • The EOD is -0.998. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.909. Based on the earnings, the company is expensive. -2
  • The TTM is -0.974. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.998MRQ-0.909-0.090
MRQ-0.909TTM-0.974+0.065
TTM-0.974YOY-7.993+7.019
TTM-0.9745Y10.583-11.556
5Y10.58310Y17.088-6.505
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-0.998-0.332-0.666
MRQ-0.909-0.483-0.426
TTM-0.974-0.417-0.557
YOY-7.993-0.253-7.740
3Y13.8390.171+13.668
5Y10.5838.472+2.111
10Y17.0887.601+9.487
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ProPhase Labs Inc:

  • The EOD is -5.290. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.815. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.597. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.290MRQ-4.815-0.475
MRQ-4.815TTM-3.597-1.218
TTM-3.597YOY-14.851+11.253
TTM-3.5975Y-115.880+112.283
5Y-115.88010Y-53.871-62.009
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-5.2903.280-8.570
MRQ-4.8152.345-7.160
TTM-3.597-0.027-3.570
YOY-14.851-0.419-14.432
3Y-173.739-0.072-173.667
5Y-115.880-0.252-115.628
10Y-53.871-0.201-53.670
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ ProPhase Labs Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Diagnostics & Research industry mean).
  • A PB ratio of 1.42 means the investor is paying $1.42Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of ProPhase Labs Inc:

  • The EOD is 1.562. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.421. Based on the equity, the company is underpriced. +1
  • The TTM is 2.362. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.562MRQ1.421+0.140
MRQ1.421TTM2.362-0.940
TTM2.362YOY4.237-1.876
TTM2.3625Y6.616-4.255
5Y6.61610Y6.547+0.069
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD1.5622.180-0.618
MRQ1.4212.038-0.617
TTM2.3622.113+0.249
YOY4.2372.276+1.961
3Y4.1632.478+1.685
5Y6.6163.338+3.278
10Y6.5474.369+2.178
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of ProPhase Labs Inc.

4.8.1. Institutions holding ProPhase Labs Inc

Institutions are holding 6.567% of the shares of ProPhase Labs Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30Vanguard Group Inc0.9828040826700
2025-03-31FourWorld Capital Management LLC0.90650.09793765773765770
2025-03-31Renaissance Technologies Corp0.72170.0002299810133254.6512
2025-03-31HighTower Advisors, LLC0.55240.0001229454-7327-3.0944
2025-03-31Geode Capital Management, LLC0.548102276942416611.8736
2025-06-30Quinn Opportunity Partners LLC0.52510.0071218127-100000-31.434
2025-06-30XTX Topco Ltd0.24680.00171025061025060
2025-03-31HPM Partners LLC0.22660.000194113941130
2025-06-30Chapin Davis Inc0.19260.00878000000
2025-03-31Susquehanna International Group, LLP0.17820740122706157.6367
2025-03-31BlackRock Inc0.1658068859-783-1.1243
2025-06-30Citigroup Inc0.1432059468594680
2025-03-31Jane Street Group LLC0.1165048388483880
2025-03-31BP WEALTH MANAGEMENT, LLC0.11470.00084766500
2025-03-31State Street Corp0.107504466300
2025-03-31Bank of New York Mellon Corp0.0892037052-1-0.0027
2025-06-30United Capital Management of KS0.08350.00213470000
2025-03-31TWO SIGMA SECURITIES, LLC0.08280.00213438517942109.1163
2025-03-31JustInvest LLC0.0780.000232418324180
2025-03-31Bank of America Corp0.0651027055-9664-26.3188
Total 6.12710.1212545213+678189+26.6%

4.9.2. Funds holding ProPhase Labs Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-07-31Vanguard Institutional Extnd Mkt Idx Tr0.68840.0001285990-118220-29.2472
2025-06-30Fidelity Extended Market Index0.33760.000114023400
2025-06-30Belfund SICAV Belinvest Equity A USD Acc0.12040.0375000000
2025-06-30Fidelity Series Total Market Index0.0972040383-14118-25.9041
2025-06-30Spartan Extended Market Index Pool F0.07390.000130688293442183.3333
2025-06-30Extended Equity Market Fund K0.05450.000122629-452-1.9583
2025-06-30Fidelity Total Market Index0.053502222400
2025-06-30T. Rowe Price U.S. Equities Tr0.0406016858-442-2.5549
2025-06-30Spartan Total Market Index Pool G0.032201336400
2025-06-30Fidelity Nasdaq Composite Index0.029101207600
2024-12-31Vanguard Instl Ttl Stck Mkt Idx Tr0.0273011339-915-7.4669
2025-06-30NT Ext Equity Mkt Idx Fd - NL0.02690.00011117300
2025-06-30NT Ext Equity Mkt Idx Fd - L0.02680.00011111800
2025-06-30Northern Trust Extended Eq Market Idx0.02680.00011111800
2025-06-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.02090.00018676-22-0.2529
2025-07-31Vanguard U.S. Eq Idx Β£ Acc0.00980405700
2025-07-31State St US Extended Mkt Indx NL Cl C0.00890.0001369500
2025-06-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.00760.0001313746717.4906
2025-06-30Extended Equity Market Fund M0.00690.00012850-41-1.4182
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.00640.0001264926490
Total 1.69570.0382704258-101750-14.4%

5.3. Insider Transactions

Insiders are holding 7.99% of the shares of ProPhase Labs Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-03-10Jason Michael BarrBUY7506.48
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-06-302024-09-302024-12-312025-03-312025-06-30
Total Other Income Expense Net -613-545-1,158795-363-652-1,0151,216201



5.2. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets42,041
Total Liabilities30,605
Total Stockholder Equity11,436
 As reported
Total Liabilities 30,605
Total Stockholder Equity+ 11,436
Total Assets = 42,041

Assets

Total Assets42,041
Total Current Assets24,571
Long-term Assets17,470
Total Current Assets
Cash And Cash Equivalents 169
Short-term Investments 2
Net Receivables 20,086
Inventory 830
Other Current Assets 3,484
Total Current Assets  (as reported)24,571
Total Current Assets  (calculated)24,571
+/-0
Long-term Assets
Property Plant Equipment 3,626
Goodwill 5,231
Intangible Assets 8,459
Long-term Assets Other 154
Long-term Assets  (as reported)17,470
Long-term Assets  (calculated)17,470
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities25,626
Long-term Liabilities4,979
Total Stockholder Equity11,436
Total Current Liabilities
Short-term Debt 5,541
Short Long Term Debt 2,814
Accounts payable 15,032
Other Current Liabilities 2,261
Total Current Liabilities  (as reported)25,626
Total Current Liabilities  (calculated)25,648
+/- 22
Long-term Liabilities
Long term Debt 436
Capital Lease Obligations 4,616
Long-term Liabilities  (as reported)4,979
Long-term Liabilities  (calculated)5,052
+/- 73
Total Stockholder Equity
Common Stock29
Retained Earnings -58,899
Accumulated Other Comprehensive Income -196
Other Stockholders Equity 70,502
Total Stockholder Equity (as reported)11,436
Total Stockholder Equity (calculated)11,436
+/-0
Other
Capital Stock29
Cash and Short Term Investments 171
Common Stock Shares Outstanding 41,541
Current Deferred Revenue1,418
Liabilities and Stockholders Equity 42,041
Net Debt 5,372
Net Invested Capital 14,686
Net Working Capital -1,055
Property Plant and Equipment Gross 7,446
Short Long Term Debt Total 5,541



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-31
> Total Assets 
6,950
24,200
18,400
30,400
49,800
47,100
46,600
49,900
48,600
40,600
31,400
30,800
33,300
26,767
23,633
25,248
26,056
23,815
22,960
23,730
24,756
22,369
24,744
25,242
24,935
22,730
21,870
22,999
26,270
24,585
22,406
22,842
31,530
30,488
26,398
31,543
35,976
31,911
28,707
31,341
34,845
31,998
29,255
30,936
33,314
28,806
25,557
26,571
24,369
21,635
16,495
18,188
19,817
22,179
19,849
22,357
21,695
19,889
17,746
20,318
19,079
17,922
15,175
16,534
16,661
16,139
15,067
16,667
17,420
17,267
19,760
17,920
16,057
14,994
12,039
13,852
14,829
13,325
11,544
12,787
12,802
57,543
50,099
39,082
34,161
34,220
22,123
20,575
20,737
16,572
15,799
15,601
12,274
11,868
12,375
23,033
31,405
85,444
76,323
72,630
89,295
99,665
97,947
97,877
87,648
95,374
91,058
91,710
91,927
90,032
93,678
91,808
63,200
50,111
42,041
42,04150,11163,20091,80893,67890,03291,92791,71091,05895,37487,64897,87797,94799,66589,29572,63076,32385,44431,40523,03312,37511,86812,27415,60115,79916,57220,73720,57522,12334,22034,16139,08250,09957,54312,80212,78711,54413,32514,82913,85212,03914,99416,05717,92019,76017,26717,42016,66715,06716,13916,66116,53415,17517,92219,07920,31817,74619,88921,69522,35719,84922,17919,81718,18816,49521,63524,36926,57125,55728,80633,31430,93629,25531,99834,84531,34128,70731,91135,97631,54326,39830,48831,53022,84222,40624,58526,27022,99921,87022,73024,93525,24224,74422,36924,75623,73022,96023,81526,05625,24823,63326,76733,30030,80031,40040,60048,60049,90046,60047,10049,80030,40018,40024,2006,950
   > Total Current Assets 
6,610
22,300
16,400
28,800
49,200
46,500
45,800
49,200
47,000
39,000
29,700
28,800
30,700
24,295
20,734
22,225
23,470
20,892
20,066
20,972
22,181
19,844
22,094
22,554
22,476
20,327
19,525
20,490
23,740
22,083
20,005
20,556
24,961
24,186
20,297
25,660
30,248
26,337
23,356
26,208
29,793
27,069
24,477
26,296
28,835
24,540
21,486
22,632
20,666
18,019
13,641
15,444
17,233
16,055
13,739
16,327
15,756
14,037
11,797
14,388
13,195
12,048
9,180
10,505
10,719
10,251
8,995
10,579
11,279
11,173
13,674
15,436
13,458
12,436
9,179
10,835
11,879
10,272
8,480
9,735
9,627
49,662
42,224
33,733
28,919
31,573
19,547
18,096
18,238
14,126
13,429
13,219
9,945
9,505
10,242
17,910
15,887
67,247
58,492
43,903
61,317
72,555
70,275
70,326
60,833
61,279
54,966
49,794
47,585
45,045
44,143
42,235
30,637
24,770
24,571
24,57124,77030,63742,23544,14345,04547,58549,79454,96661,27960,83370,32670,27572,55561,31743,90358,49267,24715,88717,91010,2429,5059,94513,21913,42914,12618,23818,09619,54731,57328,91933,73342,22449,6629,6279,7358,48010,27211,87910,8359,17912,43613,45815,43613,67411,17311,27910,5798,99510,25110,71910,5059,18012,04813,19514,38811,79714,03715,75616,32713,73916,05517,23315,44413,64118,01920,66622,63221,48624,54028,83526,29624,47727,06929,79326,20823,35626,33730,24825,66020,29724,18624,96120,55620,00522,08323,74020,49019,52520,32722,47622,55422,09419,84422,18120,97220,06620,89223,47022,22520,73424,29530,70028,80029,70039,00047,00049,20045,80046,50049,20028,80016,40022,3006,610
       Cash And Cash Equivalents 
2,460
9,000
6,600
7,700
25,500
32,300
28,900
26,700
28,300
23,700
14,700
13,400
14,000
12,106
8,214
10,107
11,366
9,707
8,695
7,585
9,741
10,751
12,839
11,292
12,897
13,315
12,385
10,647
11,392
15,587
13,736
11,703
14,366
16,481
13,979
12,173
16,885
18,190
16,060
13,597
17,757
19,176
15,843
12,484
16,085
16,265
14,375
10,880
11,957
12,244
9,217
8,945
12,801
12,352
11,163
8,705
8,232
9,586
8,743
4,616
5,541
6,268
4,610
1,815
572
4,536
4,058
751
1,638
5,519
7,350
4,953
2,926
5,021
3,761
1,336
1,664
2,457
1,149
375
441
42,800
37,280
3,897
3,173
3,387
3,665
2,269
1,554
2,450
1,049
968
434
697
2,537
10,860
6,816
32,727
17,677
8,533
8,408
25,807
23,959
22,799
9,109
9,613
3,824
702
2,149
1,736
1,780
501
678
88
169
169886785011,7801,7362,1497023,8249,6139,10922,79923,95925,8078,4088,53317,67732,7276,81610,8602,5376974349681,0492,4501,5542,2693,6653,3873,1733,89737,28042,8004413751,1492,4571,6641,3363,7615,0212,9264,9537,3505,5191,6387514,0584,5365721,8154,6106,2685,5414,6168,7439,5868,2328,70511,16312,35212,8018,9459,21712,24411,95710,88014,37516,26516,08512,48415,84319,17617,75713,59716,06018,19016,88512,17313,97916,48114,36611,70313,73615,58711,39210,64712,38513,31512,89711,29212,83910,7519,7417,5858,6959,70711,36610,1078,21412,10614,00013,40014,70023,70028,30026,70028,90032,30025,5007,7006,6009,0002,460
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,641
18,765
18,327
6,776
6,866
6,687
4,229
4,685
3,760
926
840
3,339
1,403
1,639
3,531
18,574
14,328
8,855
3,543
3,539
3,678
8,328
5,946
5,280
2,565
3,127
58
1
2
0
0
2
20021583,1272,5655,2805,9468,3283,6783,5393,5438,85514,32818,5743,5311,6391,4033,3398409263,7604,6854,2296,6876,8666,77618,32718,76523,6410000000000000000000000000000050000000000000000000000000000000000000000000000000000000
       Net Receivables 
2,460
12,300
1,400
7,500
10,900
1,100
400
8,200
7,600
2,600
1,000
3,400
6,600
2,233
1,860
3,832
4,063
2,185
1,360
4,917
4,175
2,056
1,784
4,243
4,188
2,022
1,800
4,600
7,862
2,078
1,362
3,968
6,376
3,270
1,623
8,530
7,880
2,685
1,181
6,701
6,557
2,746
1,717
6,959
6,649
3,379
1,613
5,499
4,524
1,796
153
2,487
2,086
1,357
855
4,791
4,821
2,506
1,162
4,419
3,219
2,542
938
4,172
5,409
3,080
1,128
4,445
5,319
2,856
2,343
4,051
5,836
3,468
1,245
2,766
4,000
2,688
1,801
3,833
5,770
3,410
1,835
3,613
4,445
6,785
6,363
5,891
7,798
5,618
5,566
6,311
6,822
6,025
1,930
2,999
3,155
14,344
6,644
10,680
37,708
36,694
36,670
37,832
37,054
37,836
38,572
38,642
36,313
35,116
32,937
31,638
34,901
20,204
20,086
20,08620,20434,90131,63832,93735,11636,31338,64238,57237,83637,05437,83236,67036,69437,70810,6806,64414,3443,1552,9991,9306,0256,8226,3115,5665,6187,7985,8916,3636,7854,4453,6131,8353,4105,7703,8331,8012,6884,0002,7661,2453,4685,8364,0512,3432,8565,3194,4451,1283,0805,4094,1729382,5423,2194,4191,1622,5064,8214,7918551,3572,0862,4871531,7964,5245,4991,6133,3796,6496,9591,7172,7466,5576,7011,1812,6857,8808,5301,6233,2706,3763,9681,3622,0787,8624,6001,8002,0224,1884,2431,7842,0564,1754,9171,3602,1854,0633,8321,8602,2336,6003,4001,0002,6007,6008,2004001,10010,9007,5001,40012,3002,460
       Inventory 
300
800
7,400
9,900
7,700
7,300
8,500
7,900
6,500
6,700
7,100
7,100
6,200
6,018
6,671
7,026
6,918
7,633
7,337
7,006
6,508
5,976
6,620
6,346
4,527
4,409
4,546
4,526
3,753
3,954
4,295
4,270
3,455
3,417
3,761
3,998
3,900
4,228
4,797
5,042
4,262
4,164
5,877
5,803
4,812
4,312
4,621
5,074
3,001
3,246
3,100
3,180
1,405
1,134
1,153
2,368
1,682
1,345
1,594
3,518
2,688
2,611
3,141
3,414
2,051
2,147
3,289
3,273
2,521
2,212
3,248
4,180
3,292
3,277
3,705
4,891
4,331
4,072
4,349
4,198
2,736
2,155
1,966
1,992
1,531
2,010
2,386
2,717
1,903
1,611
2,026
1,886
1,459
1,703
2,047
2,138
3,039
16,026
15,169
8,510
4,600
4,680
4,509
4,912
3,976
4,311
3,623
5,054
3,841
3,758
3,867
3,966
1,143
1,145
830
8301,1451,1433,9663,8673,7583,8415,0543,6234,3113,9764,9124,5094,6804,6008,51015,16916,0263,0392,1382,0471,7031,4591,8862,0261,6111,9032,7172,3862,0101,5311,9921,9662,1552,7364,1984,3494,0724,3314,8913,7053,2773,2924,1803,2482,2122,5213,2733,2892,1472,0513,4143,1412,6112,6883,5181,5941,3451,6822,3681,1531,1341,4053,1803,1003,2463,0015,0744,6214,3124,8125,8035,8774,1644,2625,0424,7974,2283,9003,9983,7613,4173,4554,2704,2953,9543,7534,5264,5464,4094,5276,3466,6205,9766,5087,0067,3377,6336,9187,0266,6716,0186,2007,1007,1006,7006,5007,9008,5007,3007,7009,9007,400800300
       Other Current Assets 
1,390
200
1,000
3,700
5,100
5,800
8,000
6,400
4,600
6,000
6,900
4,900
3,900
3,938
3,989
1,260
1,123
1,367
2,674
1,464
2,230
1,060
851
672
864
581
794
717
734
465
612
615
764
1,018
935
960
1,583
1,233
1,318
868
1,217
984
1,039
1,051
2,918
584
877
1,179
1,184
733
1,173
832
941
1,212
568
463
1,021
600
298
1,835
1,747
627
491
1,104
2,687
488
520
4,220
3,602
586
733
2,252
1,404
670
936
3,684
7,548
1,055
2,362
1,329
943
1,297
1,143
590
3,003
1,064
357
353
296
218
103
294
304
240
602
15,772
2,476
1,238
428
1,852
1,746
3,662
1,598
1,105
2,366
3,573
3,667
2,831
2,695
4,938
5,558
6,128
2,615
3,333
3,484
3,4843,3332,6156,1285,5584,9382,6952,8313,6673,5732,3661,1051,5983,6621,7461,8524281,2382,47615,7726022403042941032182963533571,0643,0035901,1431,2979431,3292,3621,0557,5483,6849366701,4042,2527335863,6024,2205204882,6871,1044916271,7471,8352986001,0214635681,2129418321,1737331,1841,1798775842,9181,0511,0399841,2178681,3181,2331,5839609351,0187646156124657347177945818646728511,0602,2301,4642,6741,3671,1231,2603,9893,9383,9004,9006,9006,0004,6006,4008,0005,8005,1003,7001,0002001,390
   > Long-term Assets 
340
1,900
2,000
1,600
600
600
800
700
1,600
1,600
1,700
2,000
2,600
2,472
2,899
3,023
2,586
2,924
2,894
2,758
2,574
2,526
2,649
2,688
2,459
2,403
2,344
2,509
2,529
2,502
2,401
2,286
6,568
6,301
6,101
5,883
5,727
5,574
5,351
5,133
5,052
4,929
4,778
4,639
4,478
4,266
4,071
3,939
3,702
3,616
2,854
2,744
2,584
6,124
6,110
6,030
5,939
5,852
5,949
5,930
5,884
5,874
5,995
6,029
5,942
5,888
6,072
6,088
6,141
6,094
6,086
2,484
2,599
2,558
2,860
3,017
2,950
3,053
3,064
3,052
3,175
7,881
7,875
5,349
5,242
2,647
2,576
2,479
2,499
2,446
2,370
2,382
2,329
2,363
2,133
5,123
15,518
18,197
17,831
28,727
27,978
27,110
27,672
27,551
26,815
34,095
36,092
41,916
44,342
44,987
49,535
49,573
32,563
25,341
17,470
17,47025,34132,56349,57349,53544,98744,34241,91636,09234,09526,81527,55127,67227,11027,97828,72717,83118,19715,5185,1232,1332,3632,3292,3822,3702,4462,4992,4792,5762,6475,2425,3497,8757,8813,1753,0523,0643,0532,9503,0172,8602,5582,5992,4846,0866,0946,1416,0886,0725,8885,9426,0295,9955,8745,8845,9305,9495,8525,9396,0306,1106,1242,5842,7442,8543,6163,7023,9394,0714,2664,4784,6394,7784,9295,0525,1335,3515,5745,7275,8836,1016,3016,5682,2862,4012,5022,5292,5092,3442,4032,4592,6882,6492,5262,5742,7582,8942,9242,5863,0232,8992,4722,6002,0001,7001,6001,6007008006006001,6002,0001,900340
       Property Plant Equipment 
70
100
100
200
200
200
300
300
1,000
1,000
1,100
1,400
1,900
1,967
2,113
2,187
2,140
2,332
2,339
2,255
2,201
2,171
2,296
2,332
2,337
2,291
2,233
2,398
2,418
2,338
2,255
2,192
6,474
6,162
5,894
5,646
5,586
5,423
5,230
5,011
4,838
4,798
4,645
4,517
4,355
4,168
4,035
3,904
3,667
3,581
2,818
2,710
2,572
2,535
2,521
2,453
2,362
2,275
2,372
2,353
2,307
2,297
2,418
2,452
2,365
2,311
2,495
2,511
2,564
2,517
2,509
2,484
2,599
2,558
2,860
3,017
2,950
3,053
3,064
3,052
3,175
2,881
2,875
2,849
2,742
2,647
2,576
2,479
2,499
2,446
2,370
2,382
2,329
2,363
2,133
2,123
8,309
11,724
11,478
10,938
10,349
10,759
10,486
10,211
11,347
12,865
13,619
17,843
17,470
17,259
19,770
18,085
11,616
10,561
3,626
3,62610,56111,61618,08519,77017,25917,47017,84313,61912,86511,34710,21110,48610,75910,34910,93811,47811,7248,3092,1232,1332,3632,3292,3822,3702,4462,4992,4792,5762,6472,7422,8492,8752,8813,1753,0523,0643,0532,9503,0172,8602,5582,5992,4842,5092,5172,5642,5112,4952,3112,3652,4522,4182,2972,3072,3532,3722,2752,3622,4532,5212,5352,5722,7102,8183,5813,6673,9044,0354,1684,3554,5174,6454,7984,8385,0115,2305,4235,5865,6465,8946,1626,4742,1922,2552,3382,4182,3982,2332,2912,3372,3322,2962,1712,2012,2552,3392,3322,1402,1872,1131,9671,9001,4001,1001,0001,00030030020020020010010070
       Goodwill 
270
400
400
400
400
400
300
300
300
300
200
200
200
176
154
501
329
529
436
435
327
327
327
327
31
31
31
31
31
31
31
31
31
31
31
31
31
31
31
31
0
0
0
0
0
0
0
0
0
0
0
0
0
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
901
901
901
1,385
5,709
5,709
5,709
5,709
5,709
5,231
5,231
5,231
5,231
5,231
5,231
5,231
5,231
5,231
5,231
5,2315,2315,2315,2315,2315,2315,2315,2315,2315,2315,7095,7095,7095,7095,7091,38590190190100000000000000000000000003,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,577000000000000031313131313131313131313131313131327327327327435436529329501154176200200200300300300300400400400400400270
       Intangible Assets 
270
400
400
400
400
400
300
300
300
300
200
200
200
176
154
501
110
529
66
44
22
327
327
327
31
31
31
31
31
31
31
31
31
31
31
31
31
31
31
31
0
0
0
0
0
0
0
0
0
0
0
0
0
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,234
1,125
1,017
11,562
10,852
10,143
9,434
8,889
8,475
14,524
13,769
13,015
12,333
11,687
11,041
10,396
9,750
9,104
8,459
8,4599,1049,75010,39611,04111,68712,33313,01513,76914,5248,4758,8899,43410,14310,85211,5621,0171,1251,23400000000000000000000000003,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,577000000000000031313131313131313131313131313131327327327224466529110501154176200200200300300300300400400400400400270
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
505
786
836
446
591
555
502
373
354
353
356
122
111
111
111
112
164
146
94
95
140
207
236
142
151
121
122
214
131
133
122
123
98
36
35
35
35
36
34
12
3,589
3,589
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
3,577
0
0
0
0
0
0
0
0
0
0
5,000
5,000
2,500
2,500
0
0
0
0
2,446
0
0
0
0
2,133
3,000
8,166
4,447
4,435
4,842
1,068
499
2,043
2,742
1,284
0
3,473
0
0
0
0
0
0
0
0
000000003,47301,2842,7422,0434991,0684,8424,4354,4478,1663,0002,13300002,44600002,5002,5005,0005,00000000000003,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5773,5893,589123436353535369812312213313121412212115114223620714095941461641121111111111223563533543735025555914468367865050000000000000
> Total Liabilities 
1,410
12,600
5,700
7,100
8,100
4,000
1,900
3,600
4,000
3,400
1,800
2,800
7,100
4,475
2,993
4,090
4,848
2,997
2,893
3,463
3,556
2,870
3,017
4,016
6,512
5,253
5,432
6,428
5,483
4,509
3,241
3,759
9,573
8,641
6,345
8,494
10,602
7,903
5,817
7,372
9,252
8,332
9,105
9,302
10,016
7,124
6,749
6,839
6,595
6,060
5,528
5,911
5,758
6,563
6,361
7,861
8,235
7,358
5,788
7,574
7,853
7,296
6,403
6,643
5,210
4,164
4,771
5,041
4,824
4,464
6,152
7,382
5,341
5,624
3,677
3,815
6,000
5,831
5,177
6,253
6,840
6,873
3,473
2,432
1,072
1,100
1,595
876
4,233
870
1,147
1,202
1,043
1,237
1,481
12,272
20,849
32,779
28,590
24,366
30,667
33,220
29,789
29,956
24,017
35,433
31,801
35,282
42,544
45,165
49,602
53,682
55,847
34,993
30,605
30,60534,99355,84753,68249,60245,16542,54435,28231,80135,43324,01729,95629,78933,22030,66724,36628,59032,77920,84912,2721,4811,2371,0431,2021,1478704,2338761,5951,1001,0722,4323,4736,8736,8406,2535,1775,8316,0003,8153,6775,6245,3417,3826,1524,4644,8245,0414,7714,1645,2106,6436,4037,2967,8537,5745,7887,3588,2357,8616,3616,5635,7585,9115,5286,0606,5956,8396,7497,12410,0169,3029,1058,3329,2527,3725,8177,90310,6028,4946,3458,6419,5733,7593,2414,5095,4836,4285,4325,2536,5124,0163,0172,8703,5563,4632,8932,9974,8484,0902,9934,4757,1002,8001,8003,4004,0003,6001,9004,0008,1007,1005,70012,6001,410
   > Total Current Liabilities 
1,410
11,800
4,800
6,300
8,100
4,000
1,900
3,600
4,000
3,400
1,800
2,800
7,100
4,475
2,993
4,090
4,848
2,997
2,893
3,463
3,556
2,870
3,017
4,016
6,512
5,253
5,432
6,428
5,483
4,509
3,241
3,759
7,109
6,284
5,095
7,351
9,566
7,903
5,817
7,372
9,252
8,332
9,105
9,302
10,016
7,124
6,749
6,839
6,595
6,060
5,528
5,911
5,758
6,563
6,361
7,861
8,235
7,358
5,788
7,574
7,853
7,296
6,403
6,643
4,910
3,864
4,471
4,741
4,624
4,264
5,952
7,182
5,241
5,524
3,577
3,715
4,534
4,359
5,177
6,253
6,840
6,873
3,473
2,432
1,072
1,100
1,595
876
4,233
870
956
1,073
933
1,125
1,395
2,145
6,294
18,289
14,174
9,932
15,524
19,770
16,722
16,693
16,075
18,467
14,786
16,406
20,857
23,907
28,012
28,698
784
24,052
25,626
25,62624,05278428,69828,01223,90720,85716,40614,78618,46716,07516,69316,72219,77015,5249,93214,17418,2896,2942,1451,3951,1259331,0739568704,2338761,5951,1001,0722,4323,4736,8736,8406,2535,1774,3594,5343,7153,5775,5245,2417,1825,9524,2644,6244,7414,4713,8644,9106,6436,4037,2967,8537,5745,7887,3588,2357,8616,3616,5635,7585,9115,5286,0606,5956,8396,7497,12410,0169,3029,1058,3329,2527,3725,8177,9039,5667,3515,0956,2847,1093,7593,2414,5095,4836,4285,4325,2536,5124,0163,0172,8703,5563,4632,8932,9974,8484,0902,9934,4757,1002,8001,8003,4004,0003,6001,9004,0008,1006,3004,80011,8001,410
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
429
429
429
429
429
1,321
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,466
0
1,478
1,484
1,490
400
0
0
0
0
1,097
0
3,591
0
0
0
0
0
0
1,403
658
968
1,270
1,352
1,326
654
628
301
602
298
1,478
5,574
5,586
5,180
8,121
7,538
0
5,805
5,541
5,5415,80507,5388,1215,1805,5865,5741,4782986023016286541,3261,3521,2709686581,4030000003,59101,09700004001,4901,4841,47801,466000000000000000000000000000000000000001,32142942942942942900000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,466
0
0
0
1,490
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,381
3,259
2,670
3,207
2,450
2,814
2,8142,4503,2072,6703,2592,38100000000000000000000000000001,4900001,4660000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
130
900
1,300
1,400
1,100
300
700
500
800
100
300
200
400
313
460
490
764
425
316
482
819
601
913
847
395
440
683
422
524
671
536
426
978
971
546
698
772
687
525
702
886
662
1,421
736
455
477
505
627
694
291
171
346
708
306
232
761
489
314
131
726
885
822
526
537
1,296
678
1,027
1,298
1,011
992
1,399
2,108
667
1,231
646
919
990
1,562
1,372
1,968
2,156
559
916
503
562
544
445
380
437
258
442
374
432
695
844
836
3,771
7,780
7,114
2,394
7,026
8,204
4,445
1,545
5,905
4,866
4,786
5,467
9,383
11,759
13,628
15,459
13,717
13,326
15,032
15,03213,32613,71715,45913,62811,7599,3835,4674,7864,8665,9051,5454,4458,2047,0262,3947,1147,7803,7718368446954323744422584373804455445625039165592,1561,9681,3721,5629909196461,2316672,1081,3999921,0111,2981,0276781,2965375268228857261313144897612323067083461712916946275054774557361,4216628867025256877726985469719784265366715244226834403958479136018194823164257644904603134002003001008005007003001,1001,4001,300900130
       Other Current Liabilities 
1,280
10,900
3,500
4,900
7,000
3,700
1,200
3,100
3,200
3,300
1,500
2,600
6,700
4,162
2,534
3,600
4,084
2,572
2,577
2,981
2,737
2,268
2,104
3,170
6,117
4,813
4,749
6,006
4,959
3,838
2,705
3,333
5,702
4,885
4,120
6,224
8,366
5,895
5,292
6,670
8,366
7,670
7,685
8,565
9,561
6,646
6,243
6,212
5,901
5,769
5,358
5,565
5,050
6,257
6,129
7,100
7,746
7,044
5,657
6,848
6,968
6,474
5,877
6,106
3,614
3,186
3,444
3,443
3,613
3,272
4,553
5,074
4,574
4,293
2,931
2,796
3,544
2,797
2,327
2,801
3,194
4,974
1,806
1,178
507
456
355
379
3,481
385
401
581
397
336
415
1,127
1,688
9,404
5,670
4,669
3,826
4,381
2,432
3,548
2,879
6,613
2,770
-391
228
2,333
1,782
1,780
5,867
1,857
2,261
2,2611,8575,8671,7801,7822,333228-3912,7706,6132,8793,5482,4324,3813,8264,6695,6709,4041,6881,1274153363975814013853,4813793554565071,1781,8064,9743,1942,8012,3272,7973,5442,7962,9314,2934,5745,0744,5533,2723,6133,4433,4443,1863,6146,1065,8776,4746,9686,8485,6577,0447,7467,1006,1296,2575,0505,5655,3585,7695,9016,2126,2436,6469,5618,5657,6857,6708,3666,6705,2925,8958,3666,2244,1204,8855,7023,3332,7053,8384,9596,0064,7494,8136,1173,1702,1042,2682,7372,9812,5772,5724,0843,6002,5344,1626,7002,6001,5003,3003,2003,1001,2003,7007,0004,9003,50010,9001,280
   > Long-term Liabilities 
130
800
900
800
1,100
300
700
500
800
100
300
200
400
313
460
490
764
425
316
482
912
601
913
847
395
440
683
422
0
671
536
426
2,464
2,357
1,250
1,143
1,036
2,008
525
702
886
662
1,421
736
538
477
505
627
694
291
171
346
482
306
232
761
489
314
131
726
885
822
526
537
300
300
300
300
200
200
200
200
100
100
100
100
1,466
1,472
2,850
3,452
3,646
559
916
503
562
635
497
382
643
377
191
129
110
112
86
10,127
14,555
14,490
14,416
14,434
15,143
13,450
13,067
13,263
7,942
16,966
17,015
18,876
21,687
21,258
21,590
24,984
23,713
10,941
4,979
4,97910,94123,71324,98421,59021,25821,68718,87617,01516,9667,94213,26313,06713,45015,14314,43414,41614,49014,55510,127861121101291913776433824976355625039165593,6463,4522,8501,4721,4661001001001002002002002003003003003005375268228857261313144897612323064823461712916946275054775387361,4216628867025252,0081,0361,1431,2502,3572,46442653667104226834403958479136019124823164257644904603134002003001008005007003001,100800900800130
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100
100
1,466
1,472
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,990
9,991
9,993
9,994
0
0
8,015
7,998
7,999
0
9,624
9,646
0
0
0
0
0
0
0
0
000000009,6469,62407,9997,9988,015009,9949,9939,9919,990000000000000000001,4721,46610010000000000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
300
300
300
300
200
200
200
200
100
100
100
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
191
129
110
112
86
137
162
149
121
106
905
1,301
983
927
1,283
0
3,111
0
0
0
0
0
0
0
0
000000003,11101,2839279831,30190510612114916213786112110129191000000000000001001001001002002002002003003003003000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
443
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000044300000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
5,540
11,600
12,700
23,300
41,700
43,100
44,700
46,300
44,600
37,200
29,600
28,000
26,200
22,292
20,640
20,819
20,971
20,581
19,901
20,215
21,200
19,500
21,726
21,226
18,423
17,476
16,437
16,571
20,787
20,019
19,107
19,024
21,902
21,788
19,997
22,996
25,320
23,951
22,830
23,909
25,529
23,601
20,082
21,573
23,244
21,683
18,808
19,733
17,774
15,575
10,967
12,277
14,059
15,616
13,488
14,496
13,460
12,531
11,958
12,744
11,226
10,626
8,772
9,891
11,451
11,975
10,296
11,626
12,596
12,803
13,608
10,538
10,716
9,370
8,362
10,037
8,829
7,494
6,367
6,534
5,962
50,670
46,626
36,650
33,089
33,120
20,528
19,699
16,504
15,702
14,652
14,399
11,231
10,631
10,894
10,761
10,556
52,665
47,733
48,264
58,628
66,445
68,158
67,921
63,631
59,941
59,257
56,428
49,383
44,867
44,076
38,126
7,353
15,118
11,436
11,43615,1187,35338,12644,07644,86749,38356,42859,25759,94163,63167,92168,15866,44558,62848,26447,73352,66510,55610,76110,89410,63111,23114,39914,65215,70216,50419,69920,52833,12033,08936,65046,62650,6705,9626,5346,3677,4948,82910,0378,3629,37010,71610,53813,60812,80312,59611,62610,29611,97511,4519,8918,77210,62611,22612,74411,95812,53113,46014,49613,48815,61614,05912,27710,96715,57517,77419,73318,80821,68323,24421,57320,08223,60125,52923,90922,83023,95125,32022,99619,99721,78821,90219,02419,10720,01920,78716,57116,43717,47618,42321,22621,72619,50021,20020,21519,90120,58120,97120,81920,64022,29226,20028,00029,60037,20044,60046,30044,70043,10041,70023,30012,70011,6005,540
   Common Stock
10
0
0
0
0
0
0
0
7,200
0
0
0
7,400
7
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
10
10
10
10
10
10
10
10
10
10
10
11
11
11
11
11
11
12
12
13
13
13
13
13
13
13
13
13
13
13
13
14
14
14
14
14
14
14
14
14
14
14
14
14
16
16
16
16
16
16
17
16
17
17
18
18
18
18
18
23
29
29
292923181818181817171617161616161616141414141414141414141414141313131313131313131313131212111111111111101010101010101010101099999999999999988888888888888888888888877,4000007,200000000010
   Retained Earnings 
-1,130
5,600
6,700
11,100
19,800
21,100
21,100
24,100
26,600
24,800
23,700
23,700
22,400
18,522
16,870
16,984
17,249
16,846
16,166
16,479
17,465
15,764
14,314
13,814
11,011
10,064
9,009
9,143
11,685
10,904
9,991
9,909
11,878
11,724
9,933
12,932
15,095
13,641
11,022
12,101
13,346
11,418
7,899
9,227
10,888
9,319
6,440
7,319
5,354
3,155
-1,470
-269
1,512
450
-1,804
-858
-1,989
-3,002
-3,976
-2,866
-4,699
-5,387
-7,316
-6,242
-5,790
-5,500
-7,219
-5,983
-5,385
-6,189
-9,327
-12,543
-13,219
-14,599
-16,165
-15,563
-16,819
-18,155
-19,282
-19,115
-19,687
24,952
22,646
21,869
22,144
22,187
8,986
7,929
4,533
3,520
2,282
1,854
-1,506
-2,315
-2,245
-2,653
-3,631
-2,574
-3,969
-7,947
2,642
10,490
13,231
14,198
11,753
12,303
8,863
3,722
-5,029
-11,294
-17,447
-24,034
-58,393
-54,427
-58,899
-58,899-54,427-58,393-24,034-17,447-11,294-5,0293,7228,86312,30311,75314,19813,23110,4902,642-7,947-3,969-2,574-3,631-2,653-2,245-2,315-1,5061,8542,2823,5204,5337,9298,98622,18722,14421,86922,64624,952-19,687-19,115-19,282-18,155-16,819-15,563-16,165-14,599-13,219-12,543-9,327-6,189-5,385-5,983-7,219-5,500-5,790-6,242-7,316-5,387-4,699-2,866-3,976-3,002-1,989-858-1,8044501,512-269-1,4703,1555,3547,3196,4409,31910,8889,2277,89911,41813,34612,10111,02213,64115,09512,9329,93311,72411,8789,9099,99110,90411,6859,1439,00910,06411,01113,81414,31415,76417,46516,47916,16616,84617,24916,98416,87018,52222,40023,70023,70024,80026,60024,10021,10021,10019,80011,1006,7005,600-1,130
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
41,112
41,237
41,552
41,640
41,715
41,760
42,867
43,101
43,141
43,235
43,607
44,618
48,560
53,811
54,664
54,698
55,256
56,329
56,377
56,378
56,378
56,378
56,378
56,447
56,567
57,347
58,034
58,065
58,606
58,805
59,471
59,667
59,847
60,027
60,215
60,413
60,611
60,894
61,674
102,735
99,265
0
0
105,634
106,162
108,131
0
111,482
113,789
0
0
0
0
0
0
0
0
00000000113,789111,4820108,131106,162105,6340099,265102,73561,67460,89460,61160,41360,21560,02759,84759,66759,47158,80558,60658,06558,03457,34756,56756,44756,37856,37856,37856,37856,37756,32955,25654,69854,66453,81148,56044,61843,60743,23543,14143,10142,86741,76041,71541,64041,55241,23741,1120000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000-54,138-51,015-49,55700-47,490-47,490-47,490-47,490-47,490-47,490-47,490-47,490-47,490-47,490-47,490-47,025-47,025-47,025-47,025-42,544-32,600-30,742-30,742-30,742-30,742-30,742-30,742-30,742-30,742-30,742-30,742-30,742-25,637-25,637-25,637-25,637-25,637-25,637-25,637-25,637-25,637-25,637-25,637-25,637-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,188-25,158-25,044-25,044-25,0440000000000000
   Other Stockholders Equity 
6,660
6,000
6,000
12,200
22,000
22,100
23,700
22,300
10,800
12,600
5,900
31,500
-3,600
3,763
3,762
3,827
3,714
3,727
3,727
3,727
3,727
3,727
7,404
7,404
7,404
7,404
7,420
7,420
10,539
9,107
9,107
9,107
10,016
10,056
10,056
10,056
10,217
10,302
11,799
11,799
12,174
12,174
12,174
12,337
-10,864,905
-10,888,119,326
-6,439,976,201
-7,319,077,276
22,635
12,411
12,428
16,537
12,538
15,156
15,282
15,344
15,439
15,523
15,924
15,600
15,915
16,003
16,078
16,123
17,230
17,464
17,504
17,598
17,970
18,981
22,923
23,069
23,922
23,956
24,514
25,587
30,343
25,636
25,636
25,636
25,636
25,705
23,967
14,803
11,009
11,040
11,581
11,780
11,981
12,177
12,357
12,537
12,725
12,923
13,121
13,404
14,184
55,245
51,775
56,317
56,145
56,077
55,147
53,993
51,105
47,529
49,789
54,132
54,694
56,283
61,703
62,339
65,921
69,714
70,502
70,50269,71465,92162,33961,70356,28354,69454,13249,78947,52951,10553,99355,14756,07756,14556,31751,77555,24514,18413,40413,12112,92312,72512,53712,35712,17711,98111,78011,58111,04011,00914,80323,96725,70525,63625,63625,63625,63630,34325,58724,51423,95623,92223,06922,92318,98117,97017,59817,50417,46417,23016,12316,07816,00315,91515,60015,92415,52315,43915,34415,28215,15612,53816,53712,42812,41122,635-7,319,077,276-6,439,976,201-10,888,119,326-10,864,90512,33712,17412,17412,17411,79911,79910,30210,21710,05610,05610,05610,0169,1079,1079,10710,5397,4207,4207,4047,4047,4047,4043,7273,7273,7273,7273,7273,7143,8273,7623,763-3,60031,5005,90012,60010,80022,30023,70022,10022,00012,2006,0006,0006,660



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue6,770
Cost of Revenue-6,920
Gross Profit-150-150
 
Operating Income (+$)
Gross Profit-150
Operating Expense-38,479
Operating Income-38,629-38,629
 
Operating Expense (+$)
Research Development594
Selling General Administrative37,885
Selling And Marketing Expenses0
Operating Expense38,47938,479
 
Net Interest Income (+$)
Interest Income0
Interest Expense-3,350
Other Finance Cost-0
Net Interest Income-3,350
 
Pretax Income (+$)
Operating Income-38,629
Net Interest Income-3,350
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-42,330-34,928
EBIT - interestExpense = -42,330
-46,169
-50,014
Interest Expense3,350
Earnings Before Interest and Taxes (EBIT)-38,980-38,980
Earnings Before Interest and Taxes (EBITDA)-32,336
 
After tax Income (+$)
Income Before Tax-42,330
Tax Provision-7,195
Net Income From Continuing Ops-49,525-49,525
Net Income-53,364
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses45,399
Total Other Income/Expenses Net-3,7013,350
 

Technical Analysis of ProPhase Labs Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of ProPhase Labs Inc. The general trend of ProPhase Labs Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine ProPhase Labs Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. ProPhase Labs Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of ProPhase Labs Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.595 < 0.78 < 0.9349.

The bearish price targets are: 0.47 > 0.443 > 0.2774.

Know someone who trades $PRPH? Share this with them.πŸ‘‡

ProPhase Labs Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of ProPhase Labs Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

ProPhase Labs Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of ProPhase Labs Inc.

ProPhase Labs Inc Daily Moving Average Convergence/Divergence (MACD) ChartProPhase Labs Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of ProPhase Labs Inc. The current adx is .

ProPhase Labs Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of ProPhase Labs Inc.

ProPhase Labs Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of ProPhase Labs Inc.

ProPhase Labs Inc Daily Relative Strength Index (RSI) ChartProPhase Labs Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of ProPhase Labs Inc.

ProPhase Labs Inc Daily Stochastic Oscillator ChartProPhase Labs Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of ProPhase Labs Inc.

ProPhase Labs Inc Daily Commodity Channel Index (CCI) ChartProPhase Labs Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of ProPhase Labs Inc.

ProPhase Labs Inc Daily Chande Momentum Oscillator (CMO) ChartProPhase Labs Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of ProPhase Labs Inc.

ProPhase Labs Inc Daily Williams %R ChartProPhase Labs Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of ProPhase Labs Inc.

ProPhase Labs Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of ProPhase Labs Inc.

ProPhase Labs Inc Daily Average True Range (ATR) ChartProPhase Labs Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of ProPhase Labs Inc.

ProPhase Labs Inc Daily On-Balance Volume (OBV) ChartProPhase Labs Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of ProPhase Labs Inc.

ProPhase Labs Inc Daily Money Flow Index (MFI) ChartProPhase Labs Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for ProPhase Labs Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-04-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-20MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-07-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-08STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-09-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

ProPhase Labs Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of ProPhase Labs Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.450
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of ProPhase Labs Inc with someone you think should read this too:
  • Are you bullish or bearish on ProPhase Labs Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about ProPhase Labs Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about ProPhase Labs Inc

I send you an email if I find something interesting about ProPhase Labs Inc.


Comments

How you think about this?

Leave a comment

Stay informed about ProPhase Labs Inc.

Receive notifications about ProPhase Labs Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.